Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 jun 2016 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos' R&D Update 2016
Bericht
- C1 corrector GLPG2222 for cystic fibrosis (CF) and GLPG1972 in osteoarthritis well-tolerated and no emerging safety signals observed in healthy volunteers
- GLPG1972 strongly reduces OA cartilage breakdown biomarker within two weeks
- New pre-clinical candidates GLPG2938 for idiopathic pulmonary fibrosis and GLPG2534 for atopic dermatitis
- Deep pipeline of inflammation, fibrosis, metabolic, and anti-infective programs based on novel mechanisms of action
- Building pipeline with the aim to initiate one Phase 3 program every two years and three clinical Proofs-of-Concept per year
Datum laatste update: 14 maart 2026